4.6 Article

1,8-Cineole Ameliorates Advanced Glycation End Products-Induced Alzheimer's Disease-like Pathology In Vitro and In Vivo

期刊

MOLECULES
卷 27, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/molecules27123913

关键词

1,8-cineole; Alzheimer's disease; advanced glycation end products; tau hyperphosphorylation; beta-amyloid

资金

  1. National Natural Science Foundation of China [82160823, 82160958, 81660720, 81660675]
  2. Central Government Funds for Guiding Local Scientific and Technological Development of Inner Mongolia Autonomous Region [2021ZY0014]
  3. Program for Young Talents of Science and Technology in Universities of Inner Mongolia Autonomous Region [NJYT-20-B24]
  4. Natural Science Foundation of Inner Mongolia [2018JQ01]
  5. Ph.D. Science Research Initiation Foundation of Inner Mongolia Minzu University [BS406]
  6. Inner Mongolia Key Laboratory of Mongolian Medicine Pharmacology for Cardio-Cerebral Vascular System [MDK2017039]

向作者/读者索取更多资源

Advanced glycation end products (AGEs) are important risk factors for the development and progression of Alzheimer's disease (AD). 1,8-cineole (CIN) can ameliorate tau phosphorylation and reduce Aβ production by inhibiting the activity of GSK-3β and BACE-1, highlighting its therapeutic potential for AD.
Advanced glycation end products (AGEs) are stable products produced by the reaction of macromolecules such as proteins, lipids or nucleic acids with glucose or other reducing monosaccharides, which can be identified by immunohistochemistry in the senile plaques and neurofibrillary tangles of Alzheimer's disease (AD) patients. Growing evidence suggests that AGEs are important risk factors for the development and progression of AD. 1,8-cineole (CIN) is a monoterpenoid compound which exists in many plant essential oils and has been proven to have neuroprotective activity, but its specific effect and molecular mechanisms are not clear. In this study, AGEs-induced neuronal injury and intracerebroventricular-AGE animals as the possible models for AD were employed to investigate the effects of CIN on AD pathology as well as the molecular mechanisms involved both in vivo and in vitro. Our study demonstrated that CIN could ameliorate tau phosphorylation by down-regulating the activity of GSK-3 beta and reducing A beta production by inhibiting the activity of BACE-1 both in vivo and in vitro. It is suggested that CIN has certain therapeutic value in the treatment of AD.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据